Group 1: Company Overview and Financial Performance - The company specializes in antennas, wireless charging modules, EMI/EMC devices, precision connectors, acoustic devices, automotive interconnect products, and passive components, serving global tech giants in various fields including consumer electronics and satellite communication [1][2]. - In 2024, the company achieved a total revenue of approximately CNY 8.744 billion, representing a year-on-year growth of 15.85%, and a net profit of about CNY 662 million, with a year-on-year increase of 26.89% [2]. - R&D investment for 2024 was around CNY 708 million, accounting for 8.10% of total revenue, indicating a strong commitment to innovation [2]. Group 2: Market Position and Competitive Advantage - The company is recognized as a national high-tech enterprise and a core supplier of antennas for many tech firms, having been awarded the "Manufacturing Single Champion Enterprise" title by the Ministry of Industry and Information Technology in June 2024 [4]. - The company maintains a competitive edge through continuous R&D investment, with over 8% of annual revenue allocated to innovation, focusing on core materials and technologies [3][4]. Group 3: Challenges and Strategic Responses - The company faces challenges from fluctuating demand in the consumer electronics sector and competition in pricing, necessitating a focus on technological advancements and maintaining a leading position [3][6]. - To combat potential issues of fraud, the company emphasizes strong internal governance, including optimizing shareholding structure, enhancing board independence, and strengthening internal audits [6]. Group 4: Future Growth Opportunities - The company is exploring growth opportunities in emerging fields such as data centers, artificial intelligence, low-altitude flight, and humanoid robots, indicating a proactive approach to market trends [2]. - The company is optimistic about the commercial satellite communication sector and is already providing terminal equipment connectors and antenna products to North American clients, with plans to expand its offerings [8]. Group 5: Share Buyback and Market Confidence - The company initiated its first share buyback in 2024, which has positively impacted market confidence and stock price stability, with plans to continue this strategy as opportunities arise [7].

Group 1: Business Overview - The company operates in four major business segments: polyester materials, new energy materials, synthetic biological materials, and plastic additives [2][3]. - Polyester materials include biodegradable products and special polyesters (PETG/PCTG), with significant sales growth expected [2][3]. - The engineering plastic additives segment is projected to achieve revenue of over 1 billion CNY in 2024, with a year-on-year growth rate exceeding 200% [4]. Group 2: Engineering Plastic Additives - The rapid growth of the engineering plastic additives business is attributed to high demand in industries such as automotive, electronics, and communications [4]. - The company has a production capacity of 20,000 tons and plans to expand to 60,000 tons to meet increasing market demand [4]. Group 3: New Energy Materials - The new energy materials segment includes black phosphorus and battery binder materials, with plans for a ton-level pilot production line expected to be operational in Q3 2025 [3][6]. - Black phosphorus has a theoretical capacity seven times that of graphite, making it a promising material for battery applications [7]. Group 4: Challenges and Innovations - The company faces challenges in the low-cost industrialization of black phosphorus due to the need for high-temperature and high-pressure conditions [6]. - The company has developed proprietary technologies that enhance the efficiency and yield of black phosphorus production, positioning it for successful industrialization [6]. Group 5: Market Applications - Black phosphorus can be used in various applications, including high-performance battery anodes and specialized flame retardants [7][8]. - The company is actively pursuing collaborations with downstream applications in new energy and other sectors [8]. Group 6: Risk Considerations - There are potential risks associated with the progress of new business areas, and investors are advised to review the company's periodic reports for detailed risk factors [8].

Group 1: Company Overview and Recent Performance - The company maintains high factory capacity utilization due to ongoing demand in the computing and automotive electronics markets [1] - The PCB business focuses on high-end products, primarily serving communication devices, data centers, and automotive electronics [1][2] Group 2: PCB Business Developments - The PCB business has seen increased demand for high-performance products driven by advancements in AI technology and high-speed networks [2] - The company is expanding its PCB production capacity through technological upgrades and new projects in various locations, including Shenzhen, Wuxi, Nantong, and Thailand [3] Group 3: Thailand Factory Investment - The total investment for the Thailand factory is 1.274 billion RMB, aimed at enhancing the company's capabilities in high-layer and HDI PCB technologies [4] Group 4: Packaging Substrate Business - The packaging substrate business has shown improvement in demand, particularly for storage products, compared to Q4 2024 [5] - The FC-BGA packaging substrate can produce products with up to 20 layers and has a minimum line width capability of 9/12μm [6][7] Group 5: Raw Material Price Impact - The prices of key raw materials, such as copper foil and gold salt, have increased in Q1 2025 compared to Q4 2024, affecting overall costs [7] Group 6: Electronic Assembly Business Strategy - The electronic assembly business focuses on communication, data centers, medical, and automotive electronics, aiming to provide integrated solutions and enhance customer loyalty [7]

Group 1: AI and Technology Integration - Hanshu Technology focuses on integrating AI technologies such as machine vision and big data analysis with digital retail scenarios to enhance operational efficiency and consumer experience [3] - The company is actively exploring AIoT applications and has partnered with Microsoft to leverage Azure Open AI for innovative retail solutions [3] - Hanshu Technology has established a competitive edge as the first partner in China to receive "Certified Software Designation for Retail AI" from Microsoft [3] Group 2: Electronic Price Tags Market - The global penetration rate of electronic price tags remains low, with France leading at over 40% [4] - Major markets like China, the USA, and Japan have significant growth potential due to their low penetration rates [4] - Future growth drivers include market penetration increases, replacement demand for existing electronic price tags, and the provision of SaaS and technical services [4] Group 3: Revenue and Market Strategy - Approximately 10% of the company's revenue comes from the US market, which has been minimally impacted by recent tariff increases [5] - The company is focusing on strategic expansion in Europe, Japan, Australia, Southeast Asia, and within China to mitigate tariff risks [6] - Hanshu Technology is committed to monitoring tariff policy changes and adjusting production and operational strategies accordingly [6] Group 4: Robotics and New Business Development - The company emphasizes research and application of AI technologies in robotics, having secured multiple patents for inspection robots [6] - Hanshu Technology is developing various solutions, including smart shopping carts and AI cameras, to support digital transformation in retail [6] - A commercial partnership has been established for smart shopping carts with a leading overseas client, enhancing operational efficiency and consumer experience [6]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from multiple securities and funds [2] - The meeting took place at the company's headquarters on June 5, 2025 [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2] - The meeting involved discussions with the board secretary and investor relations management [2]

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a 13.66% increase [2] - The net cash flow from operating activities was 714 million CNY, showing a significant growth of 35.39% [2] - The weighted average return on equity was 4.86%, an increase of 0.68 percentage points year-on-year [2] - The company held cash and cash equivalents of 11.062 billion CNY, with total assets amounting to 54.253 billion CNY [2] Pharmaceutical Business Growth - The pharmaceutical segment focused on "comprehensive management of pain in the injury field" as a strategic direction [3] - The segment enhanced its core products' efficacy in pain management through academic clinical research [4] - Key areas of focus included cardiovascular, respiratory, and pediatric medicine, with ongoing efforts to enrich the product pipeline [4] - Marketing strategies included the successful cultivation of proprietary sports IP, which contributed to brand youthfulness and increased product penetration [4] Oral Care Product Performance - In 2024, Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [5] - During major sales events like "618" and "Double Eleven," the brand consistently ranked first in online oral care sales [5] - Content marketing initiatives, such as the "Healthy Oral 123 Plan," significantly enhanced brand visibility, achieving over 6.43 billion exposures [6] Dividend Distribution - For the 2024 fiscal year, the company announced a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [7] - The total cash dividend for 2024, including special dividends, amounted to 23.98 CNY per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising stability and safety results reported in November [9] - The company’s subsidiary received approval for clinical trials of INR102, an innovative drug for treating metastatic castration-resistant prostate cancer [9]

Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a growth of 13.66% [2] - The net cash flow from operating activities was 714 million CNY, an increase of 35.39% [2] - The weighted average return on equity was 4.86%, up by 0.68 percentage points year-on-year [2] - The company had a cash balance of 11.062 billion CNY and total assets of 54.253 billion CNY [2] Pharmaceutical Business Development - The pharmaceutical segment focused on establishing itself as the leading brand in pain management, launching a new pain management model [3] - Key areas of focus included cardiovascular, respiratory, and pediatric medicine, enhancing the product pipeline [4] - Clinical research in diabetes foot, skeletal pain, and other areas showed steady progress, expanding product application scenarios [4] - Marketing efforts included the successful promotion of the proprietary sports IP "Let's Go Play Ball," enhancing brand youthfulness [4] - The company optimized its operational platform, achieving significant quality and efficiency improvements throughout the year [4] Health Products Channel Development - The company has a well-established national sales team for health products, maintaining a leading market share in toothpaste [5] - Continuous optimization of the entire channel has strengthened traditional offline advantages while exploring new retail formats [6] - The channel advantages have significantly enhanced market competitiveness and laid a foundation for new product commercialization [6] Future Development Strategy - The company aims for growth through both "internal" and "external" collaborative development, optimizing its industrial portfolio [7] - "Internal" development focuses on enhancing efficiency and stability across the pharmaceutical, health, and distribution sectors [7] - "External" development involves strategic mergers and collaborations to overcome growth bottlenecks and build a sustainable industrial system [7] Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, with no stock dividends [8] - A special dividend of 12.13 CNY per 10 shares was completed in November 2024, totaling 2.164 billion CNY [8] - The total cash dividend for 2024 amounts to 23.98 CNY per 10 shares, totaling 4.279 billion CNY, which is 90.09% of the net profit attributable to shareholders [9]

Group 1: Company Overview and Strategy - The company focuses on real estate development and sales, with a strong presence in the Yangtze River Delta region, adhering to a "long-termism" philosophy and a strategy of "steady operation and progress" [2][3] - The company maintains a "low debt, high return" operational strategy while advancing its dual business model in real estate and medical aesthetics [2][3] Group 2: Real Estate Business Performance - The real estate sector remains under pressure, but market sales data is stabilizing; the company benefits from ample quality land reserves and low land costs, with a total land reserve of over 1.7 million square meters [3] - Key projects like Binjiang Yayuan and Rongjin Ruifu are performing well, with strong sales and high profitability [3][4] Group 3: Future Development Plans in Real Estate - The company plans to continue its high-profit and positive cash flow real estate projects, with new projects set to launch in advantageous areas in the second half of the year [4] - The company will focus on upgrading and launching premium projects while maintaining a stable pricing system [4] Group 4: Medical Aesthetics Business Performance - The company has established six medical aesthetics institutions, creating a distribution pattern across six cities, and is committed to compliance and quality management [5][6] - The revenue and profit from the medical aesthetics sector are gradually increasing, with expectations for significant growth in revenue share by 2026 as new institutions open in the Yangtze River Delta [6] Group 5: Market Conditions and Future Outlook for Medical Aesthetics - The medical aesthetics market is experiencing a slowdown, with increased concentration and the exit of smaller players; however, the company focuses on high-end clientele and maintains a stable pricing strategy [7][8] - The company aims to expand its medical aesthetics business while exploring new industries and opportunities for sustainable growth [8]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from Dongwu Securities, Ruijun Asset, and Shiyin Fund [2] - The meeting took place on June 4, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2] - The meeting involved discussions on relevant questions regarding the company's performance [2] Group 3: Attendees - Company representatives included securities affairs representative Li Mengjue and investor relations manager Yang Kexin [2] - The meeting featured a total of four attendees from various investment firms [2]

Group 1: Financial Performance - In 2024, the company achieved a total revenue of 173,658.72 million CNY, representing a year-on-year growth of 8.53% [3] - The gas supply and related income accounted for 16.55 billion CNY, making up 95.28% of total revenue, with a year-on-year increase of 9.35% [4][5] Group 2: Business Development Strategies - The growth in urban gas business revenue was primarily driven by market expansion measures, including the renovation of old residential areas and the "bottle-to-pipe" policy, which added 28,000 new users, bringing the total service users to 548,000, a 5.38% increase [3] - The company is focusing on a diversified gas supply system and enhancing infrastructure through self-built projects, such as the Dalian distribution station, to strengthen supply capabilities [4] Group 3: Safety and Innovation - The company has implemented comprehensive safety management measures, maintaining a "three-zero" safety production standard through regular inspections and increased hazard identification efforts [4] - Future plans include expanding into hydrogen and photovoltaic industries, enhancing service quality, and optimizing existing user potential while exploring new demand [4] Group 4: Market Position and Shareholder Engagement - The company has initiated a share repurchase plan, completing the buyback of 3,226,800 shares, which is 0.8998% of the total share capital, with an investment of approximately 17 million CNY, signaling confidence in long-term development [4] - The company emphasizes the importance of value management and aims to solidify its core business while exploring innovative business models [4]